Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76

Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57

Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol (2012) 1.49

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res (2009) 1.20

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res (2005) 1.17

Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol (2004) 1.12

Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res (2000) 1.11

HER2 breast cancer therapies: a review. Biologics (2009) 1.09

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs (2005) 1.08

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs (2005) 1.05

Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer (2014) 1.00

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer (2012) 0.96

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin. Evid Based Complement Alternat Med (2011) 0.95

Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. Int J Cell Biol (2013) 0.93

Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92

Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat (2015) 0.90

Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol (2015) 0.89

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem (2013) 0.88

BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One (2014) 0.87

Assignment of backbone 1H, 13C, and 15N resonances of human Grb7-SH2 domain in complex with a phosphorylated peptide ligand. J Biomol NMR (2002) 0.87

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol (2002) 0.87

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer (2010) 0.87

Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer (2010) 0.87

Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. PLoS One (2013) 0.87

The cell migration protein Grb7 associates with transcriptional regulator FHL2 in a Grb7 phosphorylation-dependent manner. J Mol Recognit (2008) 0.86

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care (Basel) (2010) 0.86

Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. PLoS One (2012) 0.85

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer (2000) 0.85

Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84

A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications. Breast Cancer Res (2012) 0.84

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol (2009) 0.83

Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) (2012) 0.83

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res (2015) 0.83

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy. Oncotarget (2014) 0.82

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics (2015) 0.81

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. J Gastroenterol (2014) 0.80

Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci (2008) 0.79

Dimerization in the Grb7 protein. J Mol Recognit (2012) 0.78

HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array. Clin Proteomics (2014) 0.78

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today (2015) 0.77

Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag (2015) 0.77

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. J Cancer Res Clin Oncol (2013) 0.77

Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med (2014) 0.77

HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery. Theranostics (2016) 0.76

Grb7 and Filamin-a associate and are colocalized to cell membrane ruffles upon EGF stimulation. J Mol Recognit (2013) 0.76

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer (2010) 0.76

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Mol Clin Oncol (2015) 0.75

Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75

From the editor's desk: the emergence of "personalized medicine" in medical care. Mcgill J Med (2007) 0.75

Thermoresponsive Collagen/Cell Penetrating Hybrid Peptide as Nanocarrier in Targeting-Free Cell Selection and Uptake. Anal Chem (2016) 0.75

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) (2014) 0.75

NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. Syst Rev (2015) 0.75

The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget (2016) 0.75

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis. Breast Care (Basel) (2016) 0.75

The impact of race in male breast cancer treatment and outcome in the United States: a population-based analysis of 4,279 patients. Int J Breast Cancer (2014) 0.75

The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomark Res (2016) 0.75

HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer. Oncol Lett (2017) 0.75

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)/HER2(pos) early breast cancer. Oncoimmunology (2016) 0.75

A simple index to predict prognosis independent of axillary node information in breast cancer. Aust N Z J Surg (1997) 2.71

Cloning and screening with nanogram amounts of immunopurified mRNAs: cDNA cloning and chromosomal mapping of cystathionine beta-synthase and the beta subunit of propionyl-CoA carboxylase. Proc Natl Acad Sci U S A (1986) 1.94

Restrictions on smoking at home and urinary cotinine levels among children with asthma. Am J Prev Med (2000) 1.81

P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res (2001) 1.74

Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol (1995) 1.58

Risk factors for repeat attendance at hospital emergency departments among adults and children with asthma. Aust N Z J Med (1997) 1.48

Hip fracture rates in South Australia: into the next century. Aust N Z J Surg (2000) 1.38

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol (2001) 1.35

Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res (1998) 1.33

A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer (1999) 1.31

Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res (1994) 1.31

A population-based study of the coverage of cancer patients by hospice services. Palliat Med (1996) 1.18

Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer (1989) 1.17

Population-based study of prognostic factors in stage II colonic cancer. Br J Surg (2006) 1.16

Simple day-case surgery for pilonidal sinus disease. Br J Surg (2011) 1.15

Expression of amplified DNA sequences for ornithine transcarbamylase in HeLa cells: arginine residues may be required for mitochondrial import of enzyme precursor. J Cell Biol (1985) 1.14

Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol (1999) 1.12

Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res (2001) 1.11

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer (2006) 1.10

A comparative study of some commercially available tests for rheumatoid factor. J Clin Pathol (1974) 1.09

RNA required for import of precursor proteins into mitochondria. Science (1984) 1.08

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene (1997) 1.08

The significance of oncogene amplification in primary breast cancer. Int J Cancer (1989) 1.06

Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes (1999) 1.06

Isolation and characterization of dihydropteridine reductase from human liver. Biochem J (1981) 1.05

Characteristics of responding-, nonresponding- and refusing-parents in an adolescent lifestyle choice study. Eval Rev (2001) 1.05

Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer (1995) 1.04

Continuous passive motion after primary total knee arthroplasty. Does it offer any benefits? J Bone Joint Surg Br (1997) 1.02

Human dihydropteridine reductase: a method for the measurement of activity in cultured cells, and its application to malignant hyperphenylalaninemia. Clin Chim Acta (1979) 1.02

Large DNA fragment sizing using native acrylamide gels on an automated DNA sequencer and GENESCAN software. Biotechniques (1998) 1.01

Heterogeneity of the molecular defect in human dihydropteridine reductase deficiency. Biochem J (1981) 0.98

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol (2001) 0.98

Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res (1996) 0.97

Isolation of fetal trophoblast cells from peripheral blood of pregnant women. Lancet (1990) 0.96

Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res (1997) 0.95

Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer (1996) 0.94

Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res (1998) 0.93

Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Br J Cancer (1986) 0.93

Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer (1996) 0.93

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol (1995) 0.92

Prevalence of non-specific health symptoms in South Australia. Int J Environ Health Res (2001) 0.91

Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer (1996) 0.91

Molecular and immunological comparison of human dihydropteridine reductase in liver, cultured fibroblasts and continuous lymphoid cells. Biochem J (1981) 0.90

Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer (1996) 0.90

Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer. Prostate (2004) 0.89

Dihydropteridine reductase deficiency diagnosis by assays on peripheral blood cells. Lancet (1980) 0.87

Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. Prostate (1987) 0.87

The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer (1994) 0.87

A comparison of methods for measuring intestinal antibodies against Vibrio cholerae in mice. Aust J Exp Biol Med Sci (1979) 0.86

Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res (1999) 0.86

Prenatal determination of dihydropteridine reductase in a normal fetus at risk for malignant hyperphenylalaninemia. Prenat Diagn (1983) 0.85

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood (1996) 0.85

Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues. J Urol (1995) 0.84

Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus. Diabet Med (1997) 0.84

Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids (1995) 0.83

Modifications of the local immune response to Vibrio cholerate attributed to the intestinal microbial flora of the mouse. Aust J Exp Biol Med Sci (1978) 0.83

Rapid detection of the factor V Leiden (1691 G > A) and haemochromatosis (845 G > A) mutation by fluorescence resonance energy transfer (FRET) and real time PCR. J Clin Pathol (1999) 0.83

Intestinal antibody to Vibrio cholerae in immunised mice. Aust J Exp Biol Med Sci (1979) 0.82

Understanding a ductal carcinoma in situ diagnosis: patient views and surgeon descriptions. Eur J Cancer Care (Engl) (2011) 0.82

Dinucleotide repeat polymorphisms isolated by the polymerase chain reaction. Biotechniques (1993) 0.81

Dihydropteridine reductase deficiency diagnosis by assays on peripheral blood-cells. Lancet (1979) 0.80

In vitro degradation of mouse, rabbit and dog antibodies to Vibrio cholerae by succus entericus. Aust J Exp Biol Med Sci (1978) 0.80

Changes in the immunoglobulin levels of the mouse gut and serum during conventionalisation and following administration of Salmonella typhimurium. Aust J Exp Biol Med Sci (1978) 0.79

Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol (1998) 0.79

The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma. J Urol (1991) 0.79

Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry (2012) 0.79

Origins of polymorphism at a polypurine hypervariable locus. Nucleic Acids Res (1993) 0.79

A case of aortic aneurysm with bilateral ureteric obstruction,. Aust N Z J Surg (1972) 0.78

Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF. Breast Cancer Res Treat (1991) 0.78

Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cell Dev Biol (1989) 0.78

The effect of tamoxifen on the growth of human malignant melanoma in vitro. Eur J Cancer Clin Oncol (1984) 0.78

Coverage of cancer patients by hospice services, South Australia, 1990 to 1993. Aust N Z J Public Health (1998) 0.78

Specific binding of oestradiol to guinea-pig prostate cytosol and nuclear fractions. J Steroid Biochem (1985) 0.78

Tumor microvascularity has no independent prognostic significance for breast cancer. Pathology (1998) 0.78

A highly polymorphic polypurine sequence on chromosome 8 (D8S210). Hum Mol Genet (1992) 0.77

Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. Prostate (1989) 0.77

Use of naphthoquinone adsorbent for the isolation of human dihydropteridine reductase. Methods Enzymol (1987) 0.77

Effects of ageing and hormonal manipulations on the level of oestrogen receptors in the guinea-pig prostate. J Endocrinol (1987) 0.76

Epidermal growth factor receptor in breast cancer: storage conditions affecting measurement, and relationship to steroid receptors. Breast Cancer Res Treat (1992) 0.76

Clinical pharmacy services provided to an emergency department. Can J Hosp Pharm (1992) 0.76

Cervical spine injuries in road traffic crashes in South Australia, 1981-86. Aust N Z J Surg (1989) 0.75

The titre of bactericidal antibody against Salmonella gallinarum in chicks. Immunology (1970) 0.75

Effects of oestradiol-17 beta and 5 alpha-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. J Endocrinol (1994) 0.75

Comparison of three methods in surgical treatment of pilonidal disease. ANZ J Surg (2001) 0.75

The impact of publication of Australian treatment recommendations for DCIS on clinical practice: A population-based, "before-after" study. Eur J Surg Oncol (2010) 0.75